Assertio Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.9625
- Today's High:
- $3.06
- Open Price:
- $3.03
- 52W Low:
- $2.07
- 52W High:
- $8.01
- Prev. Close:
- $3.05
- Volume:
- 1798947
Company Statistics
- Market Cap.:
- $345.12 million
- Book Value:
- 4.503
- Revenue TTM:
- $162.16 million
- Operating Margin TTM:
- 35.37%
- Gross Profit TTM:
- $138.29 million
- Profit Margin:
- 59.86%
- Return on Assets TTM:
- 9.52%
- Return on Equity TTM:
- 53.56%
Company Profile
Assertio Therapeutics Inc had its IPO on 1997-11-05 under the ticker symbol ASRT.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Assertio Therapeutics Inc has a staff strength of 30 employees.
Stock update
Shares of Assertio Therapeutics Inc opened at $3.03 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.96 - $3.06, and closed at $2.97.
This is a -2.62% slip from the previous day's closing price.
A total volume of 1,798,947 shares were traded at the close of the day’s session.
In the last one week, shares of Assertio Therapeutics Inc have slipped by -10%.
Assertio Therapeutics Inc's Key Ratios
Assertio Therapeutics Inc has a market cap of $345.12 million, indicating a price to book ratio of 1.2779 and a price to sales ratio of 1.2627.
In the last 12-months Assertio Therapeutics Inc’s revenue was $162.16 million with a gross profit of $138.29 million and an EBITDA of $88.54 million. The EBITDA ratio measures Assertio Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Assertio Therapeutics Inc’s operating margin was 35.37% while its return on assets stood at 9.52% with a return of equity of 53.56%.
In Q1, Assertio Therapeutics Inc’s quarterly earnings growth was a positive 1211.2% while revenue growth was a positive 16.2%.
Assertio Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 6.1538
- Trailing PE
- 3.5028
- PEG
- 0.6155
Its diluted EPS in the last 12-months stands at $1.77 per share while it has a forward price to earnings multiple of 6.1538 and a PEG multiple of 0.6155. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Assertio Therapeutics Inc’s profitability.
Assertio Therapeutics Inc stock is trading at a EV to sales ratio of 1.2624 and a EV to EBITDA ratio of 2.5412. Its price to sales ratio in the trailing 12-months stood at 1.2627.
Assertio Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $414.27 million
- Total Liabilities
- $94.55 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Assertio Therapeutics Inc ended 2024 with $414.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $414.27 million while shareholder equity stood at $250.66 million.
Assertio Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $94.55 million in other current liabilities, 5000.00 in common stock, $-323085000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $68.60 million and cash and short-term investments were $68.60 million. The company’s total short-term debt was $470,000 while long-term debt stood at $38.15 million.
Assertio Therapeutics Inc’s total current assets stands at $137.85 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $46.47 million compared to accounts payable of $6.17 million and inventory worth $16.23 million.
In 2024, Assertio Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Assertio Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.97
- 52-Week High
- $8.01
- 52-Week Low
- $2.07
- Analyst Target Price
- $9.75
Assertio Therapeutics Inc stock is currently trading at $2.97 per share. It touched a 52-week high of $8.01 and a 52-week low of $8.01. Analysts tracking the stock have a 12-month average target price of $9.75.
Its 50-day moving average was $4.22 and 200-day moving average was $4.99 The short ratio stood at 3.48 indicating a short percent outstanding of 0%.
Around 189.8% of the company’s stock are held by insiders while 3397.2% are held by institutions.
Frequently Asked Questions About Assertio Therapeutics Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.